Is Perspective Therapeutics, Inc. (CATX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.7% / 30% | 40.1% / 30% | 0.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.7% / 33% | 40.1% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.2% / 33% | 66.5% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.7% / 33% | 40.1% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.2% / 33% | 66.5% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -92632.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.6% | |
| Return on Assets (ROA) | -23.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$82M |
| Free Cash Flow | -$95M |
| Total Debt | $3M |
| Debt-to-Equity | 1.6 |
| Current Ratio | 5.2 |
| Total Assets | $267M |
Price & Trading
| Last Close | $4.22 |
| 50-Day MA | $4.51 |
| 200-Day MA | $3.56 |
| Avg Volume | 3.5M |
| Beta | 1.8 |
|
52-Week Range
$1.60
| |
About Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Perspective Therapeutics, Inc. (CATX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Perspective Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Perspective Therapeutics, Inc.'s debt ratio?
Perspective Therapeutics, Inc.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.2%.
What are Perspective Therapeutics, Inc.'s key financial metrics?
Perspective Therapeutics, Inc. has a market capitalization of $464M. Return on equity stands at -41.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.